ReviewSmall science2026
Regulatory T Cells and Nanomaterials: Dual Perspectives in Therapeutics and Immunomodulation.
Review in Small science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Regulatory T Cells and Nanomaterials: Dual Perspectives in Therapeutics and Immunomodulation.Small science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Regulatory T cells (Tregs) orchestrate immune tolerance, protecting against autoimmunity and promoting transplant tolerance, yet they can also facilitate tumor immune evasion. Advances in nanotechnology now permit high-precision manipulation of Treg biology. Tailored polymeric, lipid-based, inorganic, and biomimetic nanoparticles can be engineered to deliver antigens, cytokines, small-molecule drugs, antibodies, or nucleic acids that selectively expand or stabilize Tregs for tolerogenic therapy; the same design principles can be inverted to inhibit or deplete intratumoral Tregs, thereby restoring effective antitumor immunity. Beyond intentional therapies, the review also explores unintended immunological consequences of nanoparticles, such as inadvertent induction of Tregs or broader immunosuppressive responses, and how Tregs can conversely limit the efficacy of nanoparticle-based vaccines or cancer nanotherapies. Outstanding challenges related to targeting efficiency, safety, manufacturability, and combinatorial therapeutic strategies are outlined, and prospective avenues for future investigation are highlighted. Collectively, emerging data position Treg-focused nanomedicine as a versatile and clinically relevant toolkit for restoring or unleashing immunity across autoimmunity, transplantation, and oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.